Previous 10 | Next 10 |
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has completed enrollment in REACH, a Pha...
2023-08-28 17:17:30 ET Gainers: Fate Therapeutics ( NASDAQ: FATE ) +5% . Diversified Healthcare ( DHC ) +4% . Taysha Gene Therapies ( TSHA ) +3% . Afya ( AFYA ) +3% . Iris Energy ( IREN ) +2% . Losers: Kodiak Sc...
2023-08-22 12:47:19 ET Gainers: VinFast Auto ( VFS ) +123% . AMTD Digital ( HKD ) +67% . Fulcrum Therapeutics ( FULC ) +51% . Hitek Global ( HKIT ) +30% . Fabrinet ( FN ) +28% . BioNexus Gene Lab Corp. ( BGLC ) +22% ....
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is one today's most active stocks by volume. So far today, approximately 63.93M shares of Fulcrum Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 787.16k shares. Fulcrum Therapeutics, Inc., a clinical-stage biopharmac...
2023-08-22 11:56:20 ET More on Fulcrum Therapeutics Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD Fulcrum inks licensing deal for rare blood disorder Fulcrum slips as Goldman Sachs downgrades on limited catalyst path Seeking A...
2023-08-22 10:00:48 ET Gainers: Fulcrum Therapeutics ( FULC ) +55% . Renovaro Biosciences ( RENB ) +18% . ProMIS Neurosciences ( PMN ) +17% . cbdMD ( YCBD ) +9% . 60 Degrees Pharmaceuticals ( SXTP ) +7% . Losers: Emergent BioSo...
2023-08-22 09:27:19 ET Fulcrum Therapeutics ( FULC ) +36% as FDA lifts clinical hold on sickle-cell disease candidate . ProMIS Neurosciences ( PMN ) +30% on $20.4M private placement . Fabrinet ( FN ) +24% on Q4 earnings release . Hallmark Fi...
2023-08-22 08:09:03 ET More on Fulcrum Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD Fulcrum inks licensing deal for rare blood disorder Fulcrum slips as Goldman Sachs downgrades on limited catalyst path Fulcrum Therapeutics d...
CAMBRIDGE, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the U.S. Food and Drug Administration (FDA) ...
2023-08-05 05:18:06 ET Fulcrum Therapeutics, Inc. (FULC) Q2 2023 Earnings Conference Call August 03, 2023, 08:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alexander Sapir - President and Chief Executive Officer Iain Fraser - Interim Chief...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...